scPharmaceuticals Inc SCPH.OQ SCPH.O is expected to show a rise in quarterly revenue when it reports results on March 11 (estimated) for the period ending December 31 2024
The Burlington Massachusetts-based company is expected to report a 98.2% increase in revenue to $12.084 million from $6.1 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for scPharmaceuticals Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for scPharmaceuticals Inc is $17.50, above its last closing price of $3.12.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.29 | -0.30 | -0.75 | Missed | -153 |
Jun. 30 2024 | -0.42 | -0.41 | -0.44 | Missed | -6.3 |
Mar. 31 2024 | -0.44 | -0.44 | -0.36 | Beat | 17.6 |
Dec. 31 2023 | -0.52 | -0.42 | -0.35 | Beat | 16.4 |
Sep. 30 2023 | -0.37 | -0.36 | -0.41 | Missed | -12.4 |
Jun. 30 2023 | -0.37 | -0.37 | -0.36 | Beat | 3.3 |
Mar. 31 2023 | -0.39 | -0.36 | -0.30 | Beat | 17.8 |
Dec. 31 2022 | -0.34 | -0.39 | -0.30 | Beat | 22.5 |
This summary was machine generated March 7 at 11:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments